Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2000 07:36 ET | Source: H. Lundbeck A/S

H. Lundbeck A/S' Compound for the Treatment of Anxiety Disorder - Seramesine - Enters Clinical Phase II Release No 26

COPENHAGEN, Denmark, August 14, 2000 (PRIMEZONE) -- H. Lundbeck A/S hereby announces that seramesine has just initiated clinical phase II studies. Seramesine is a compound for the treatment of...